The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call.
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joe Pantginis - HC Wainwright Laura Suriel - Alliance Resource Partners Operator Greetings and welcome to the PDS Biotechnology Third Quarter 2023 Earnings Call and Webcast.
Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck cancer. The interim analysis showed 9 confirmed responses, which increased to 14 in a later update, surpassing the efficacy threshold for the study. PDS plans to submit an amended IND application to the FDA in Q3 2023 to initiate its phase 3 VERSATILE-003 study.
PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the horizon, it seems a good time to 'circle back' on this small developmental, oncology-focused concern.
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), presented at the 2023 American Society for Clinical Oncology (ASCO) meeting.